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Cyclic AMP occupies a position of central importance in hormone biochemistry
(1, 2). Of especial interest is its possible function in mediating hormone regulation
of pigment cell metabolism. It is known to affect cell membrane properties pro-
ducing changes in sodium transport (3), water permeability (4), and hormone
release (5), the last process having some analogies to melanosome dispersion in
amphibian dermal melanocytes. The fine molecular details underlying these cyclic
AMP-mediated changes in membrane function are as little understood as the ulti-
mate molecular details of the role of cyclic AMP in pigment cells.
Our interest in the Cloudman mouse melanoma was provoked by the results
of studies done with the melanocyte system in the skin of Rana pipiens. We found
that cyclic AMP mimics the effects of melanocyte-stimulating hormone (MSH)
on frog dermal melanocytes [a dispersion of melanosomes especially into the
peripheral dendritic processes of the melanocyte] (6). This finding and the fact
that methyl xanthines (which inhibit cyclic AMP phosphodiesterase) could darken
amphibian skin were taken as partial support for the hypothesis that the regulation
of melanocyte metabolism by MSH was mediated by the adenyl-cyclase system.
Additional support for this idea was provided by Butcher and coworkers in a study
which showed that MSH could increase the cyclic AMP content of pigmented dor-
sal R. pipiens skin while having no effect on the cyclic AMP content of the unpig-
mented abdominal skin (7). An element still lacking in the proof of the MSH-cyc-
lase hypothesis was the demonstration that MSH could selectively activate adenyl
cyclase in the appropriate broken-cell preparations, especially membrane particles
derived from homogeneous collections of melanocytes. Initial attempts to pursue
this question in amphibian melanocytes were complicated by the mechanical prob-
lems encountered in preparing membrane fragments from dermal melanocytes
(associated with the abundance of collagen) and the fact that the population of
dermal melanocytes is widely dispersed among other cell types, none of which re-
spond to MSH peptides, but most of which contain cyclase molecules exhibiting
basal cyclase activity in the absence of added hormones. These difficulties were
avoided by doing these experiments on the effect of MSH in broken cells from
the Cloudman mouse melanoma, an essentially homogeneous population of mam-
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malian melanocytes which exhibited a vigorous and selective stimulation of adenyl
cyclase activity by MSH. Early studies with this system including the profile of
hormonal sensitivity which characterized the cyclase, have been described in detail
(8). The primary features of the system include responsiveness to both alpha and
beta MSH as well as to MSH peptides which have been racemized by exposure
to tenth-normal sodium hydroxide. There is the expected cross reactivity to ACTH,
no response to or inhibition by melatonin and minimal activation by catecholam-
ines. The latter observation (with melatonin and norepinephrine) are perhaps
contrary to what might have been expected in frog skin (9).
Additional interest in the melanoma from the point of view of the cyclase system
and the regulation of gene expression has derived from the recent finding by Pastan
(10) that the levels of the enzyme tyrosinase in the melanoma appear to be regu-
lated by cyclic AMP. We have examined the adenyl cyclase system from both
melanotic and relatively amelanotic varieties of the melanoma and in both instances
an excellent cyclase response to the MSH peptides in broken-cell preparations was
observed. This finding of an intact cyclase response in amelanotic cells suggests
that the complex sequence of reactions regulating pigment synthesis in the mam-
malian melanocyte, or at least the melanoma melanocyte, can be lesioned distal
to the locus of action of cyclic AMP.
In the present study, we should like to discuss some additional aspects of the
regulation and characteristics of the Cloudman melanoma adenyl cyclase system.
We will emphasize the selectivity and efficacy of prostaglandins as regulators of
this cyclase system in broken-cell preparations. The interaction of calcium with
the MSH and prostaglandin activations of adenyl cyclase in mammalian and am-
phibian melanocytes, and the failure of MSH to affect prostaglandin synthetase
activity, will be discussed. In this context we will consider the hypothesis (11)
that prostaglandins are obligatory intermediates in the activation of any cyclase
system by tissue-specific hormones. We will also consider the distribution of
melanoma cyclase in the various centrifugal fractions derived from homogenates of
melanoma, and finally the effects of various regulators on the cyclic AMP content
of melanoma slices in which cellular architecture is relatively preserved. These ob-
servations are briefly discussed in the context of current understanding of cyclic
nucleotide biochemistry as it might bear on the biochemistry of pigment cells.
MATERIALS AND METHODS
Both melanotic and relatively amelanotic strains of the S-91 Cloudman
melanoma were obtained from Dr. Harry Demopoulos of the New York University
School of Medicine. The tumors were maintained in male mice of the strain
DBA/2J (Jackson Memorial Labs.) and were transplanted under aseptic condi-
tions by intraperitoneal injection of finely minced tissue suspended in 0.15 M
saline. Tumors grew as encapsulated solid masses with adhesions to omentum and
peritoneum. The intraperitoneal location produced growth which was more ho-
mogeneous and less necrotic than the subcutaneous location. Time for appearance
of a 1-cm tumor was about 2% weeks.
Tissue was homogenized with a motor-driven Potter-Elvejhem (12 strokes,
Teflon on glass, 40) in 0.12 M potassium acetate buffer, pH 7.4, which contained
0.03 M KCL. Washed particles were prepared from the above homogenates (8).
Tissue slices (0.2-mm thickness) were made with a McElwain chopper (Ivan
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Sorvall Co.) at 40C. Slices were incubated in oxygenated Krebs-Ringer bicarbonate
for 10 min at 370C, and incubations were terminated by freezing the samples in
liquid nitrogen, grinding with a mortar and pestle, and thawing into 50% acetic
acid which contained [8-3H] cyclic AMP (Schwartz-Mann) to permit estimation
of recovery.
ACTH and MSH were provided by Drs. Lande and Lerner of Yale University.
The prostaglandins and 7-oxa-13-prostynoic acid were provided by Drs. Caldwell
and Speroff of Yale University. Indomethacin was a gift from Merck & Co. Prosta-
glandins were stored at -200C. in absolute ethanol. Immediately before use they
were dried and dissolved in the reaction buffer. Indomethacin and 7-oxa-13-
prostynoic acid were dissolved in methanol and diluted 1:40 into the broken-cell
preparations.
Cyclase activity was assayed as previously described (12). [8-14C] ATP was
used as the substrate. Labeled cyclic AMP with added cold cyclic AMP for visual-
ization was purified by descending thin-layer chromatography at 310C on poly-
ethyleneimine-cellulose for 8 hr with 1 M ammonium acetate-methanol (2:5). The
origin was then removed by shaving just behind the cyclic AMP spots, the plates
were dried, rewicked, and rechromatographed for 12 hr with 1-butanol-acetic
acid-water (2:1:1). The purified cyclic AMP still on PEI cellulose was shaved
directly into scintillation vials, dispersed by sonication, and counted with toluene
PPO cocktail in the presence of Cabosil in a Beckman LS 200 liquid scintillation
spectrometer. Assay of adenyl cyclase activity was carried out using a 3-min incu-
bation period at 370C, in the presence of 1.6 mM [8-14C] ATP (45 Ci/mole,
Schwartz-Mann), 7 mM aminophylline, and an ATP regenerating system (38 mM
phosphocreatine and 80 ,ag/ml creatine phosphokinase) in buffer 1 (3 mM MgSO4,
0.4 mM EDTA, and 32 mM glycylglycine, pH 7.4). Assay of 3'5' nucleotide phos-
phodiesterase was carried out by incubating in the presence of 10-4 M [8-14C]
cAMP (39 Ci/mole, Schwartz-Mann) in buffer 1 and measuring the disappearance
of substrate in 1 min. Protein kinase was assayed by the method of Kuo and Green-
gard (13). Protein concentrations were determined by the method of Lowry (14).
Cyclic AMP levels of tissue slices or skin were determined by the radioimmuno-
assay method of Steiner (15) with minor modifications (16).
Prostaglandin synthetase was assayed by measuring conversion of labeled
arachidonic acid to labeled prostaglandins [5,6,8,9,11,12,14,15-3H] arachidonic
acid (5000 Ci/mole, New England Nuclear) was purified just prior to use by col-
umn chromatography (17). Samples were incubated in a total volume of 0.1 ml
containing 32 mM glycylglycine buffer, pH 7.4, 10-7 M labeled and 1.6 X 10-5
M unlabeled arachidonic acid, with or without 2 X 10-5 M MSH. The incubation
was carried out at 370C in a shaking incubator under air for 20 min. The samples
were acidified to pH 2.5 with 1 N HCl, and extracted twice with 8 ml of ethyl
acetate. The combined ethyl acetate extracts were dried under nitrogen. Samples
were purified by column chromatography (17) followed by thin-layer chromatog-
raphy (18), and counted on a Packard Tri-Carb Liquid Scintillation Counter
(Model 3375). Counts were found both in the E fraction (PGE2) and in the F
fraction (PGF2). To further confirm that the counts in the E fraction were prosta-
glandin, it was converted to prostaglandin B19, rechromatographed, and the label
was found in the PGB fraction.
Darkening of dorsal frog skin (Rana pipiens) was measured by the procedure
previously described by Bitensky and Burstein (6).
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RESULTS
The sensitivity of melanoma cyclase to different prostaglandins (PG) is shown
in Fig. 1. Activation by MSH is included for comparison. The magnitude of activa-
tion by PGE1 is 11/2 to 2 times greater than that seen with MSH, but other prosta-
glandins are less effective than MSH. In the presence of saturating amounts of
PGE1, PGE2, and PGF,., MSH produces additional activation of melanoma cy-
clase (Table 1). MSH activation is also additive with the activation produced by
saturating amounts of fluoride (Table 1). The activation of cyclase by PGE1 ap-
pears to reach half maximal saturation at a concentration of 1 ug/ml. (Fig. 2).
Activation of cyclase by MSH is lowered by ethyleneglycol bis-Q(8 aminoethyl ether)
N, N, N',N' tetra-acetic acid (EGTA) and restored by calcium. Although fluoride
activation is blocked by EGTA this inhibition is not prevented or reversed by cal-
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FIG. 1. Activation of melanoma adenyl cyclase by MSH and by various prostaglandins.
Cyclase activity is nmoles cAMP/min/mg protein. MASH concentration is 50 ,tg/ml. Prosta-
glandin concentration is 10 Ag/ml.
TABLE 1
ADDITIVE EFFECTS OF MSH, PROSTAGLANDINS, AND FLUORIDE
Adenyl cyclase activitya
Regulator Without MSH With MSH
Control 1.7 5.9
MSH 5.9 5.9
PGE1 8.5 11.0
PGE2 2.6 6.8
PGF1 2.8 6.5
Fluoride 7.5 10.0
a Activities are expressed as nmoles cAMP/10 min/mg of protein. Regulator concentrations are as
follows: MSH 50 jug/ml, PGEI, PGE2, and PGF1 10 g/lml, and fluoride 10 mM. Experiments were
carried out with whole homogenate preparations,
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PGEI CONCENTRATION CURVE
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FIG. 2. Prostaglandin E1 concentration curve for activation of melanoma adenyl cyclase.
Cyclase activity is nmoles cAMP/min/mg protein.
TABLE 92
ROLE OF CALCIUM IN MELANOMA CYCLASE ACTIVATIONa
Control MSH E1 Fluoride
Control 2.0 5.5 8.0 4.5
EGTA 1.7 3.7 7.9 2.5
EGTA + Ca2+ 2.0 6.0 7.8 2.8
EGTA + Mg'+ 1.8 4.0 8.3 2.9
a Activities are expressed as a nmole cAMP/10 min/mg of protein. Reagent concentrations are as
follows: MSH 50 ,ug/ml, PGE1 10 pg/ml, fluoride 10 mM, EGTA 7 mM, Ca and Mg++ 1 mM. This
concentration of cations is in addition to the 5 mM Mg++ from the reaction mixture. Whole homoge-
nate preparations were used throughout.
cium or magnesium. PGE1 activation appears to occur without the calcium de-
pendence found for activation by MSH (Table 2).
Activation by MSH is partially blocked by 7-oxa-13-prostynoic acid (a prosta-
glandin antagonist) and by indomethacin (an inhibitor of prostaglandin synthetase).
The kinetics of inhibition by 7-oxa-13-prostynoic acid appear to be competitive
with MSH, (Fig. 3) as well as with PGE1 (data not shown). The concentrations
required for both inhibitors, however, is rather high and raised questions concern-
ing the specificity and locus of the inhibition. The 70% inhibition of MSH effects
by indomethacin (Table 3) is seen only at concentrations of inhibitor which are
100 times as large as those required for the inhibition of prostaglandin synthetase
(20).
The effects of MSH on prostaglandin synthesis were examined in melanoma.
The tritiated prostaglandin precursor (arachidonic acid) was readily converted to
PGE2 and PGF2, by melanoma homogenates. The homogenate produced 2.6
pmoles PGE2/min/mg protein and 1.0 pmoles PGF2a/min/mg protein. The rates
587KREINER ET AL.
2
V
cAMP
nM/10min/mg
Protein
0 .25 .50 1.00
20 x [MSH] (mg/ml)
FIG. 3. Inhibition of MSH activation of melanoma adenyl cyclase by
acid (75 ,ug/ml). Cyclase activity is nmoles cAMP/min/mg protein.
7-oxa-13-prostynoic
TABLE 3
INHIBITION OF CYCLASE ACTIVATION BY INDOMETHACIN
MSIL .oncentrations ,~ 0 Adenyl cyclase activity AISII concentrations
(lAglllll) 0 6.2-)5 1-2.5 25 6.~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~25~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Indomethacin
(50 ,ug/ml) 0.7 0.9 1.0 1.?2
Inidomethacin
(5 ug/ml) 12 1.4 .1 2.9
Coiitrol 1>.2 1.5 &2. 1 3.0
a Activities are expressed as nmole cAMIP/10 min/mg of protein. Whole hoinogenate preparationis
NN-ere use(l throughout.
of synthesis were not influenced by those concentrations of MSH which profoundly
activate melanoma cyclase in the same homogenate preparations.
The distribution of cyclase in melanoma homogenates was somewhat atypical
in that there was a measurable (25%) amount of the MSH-responsive cyclase
activity in a 200,000 g supernatant fraction. There is some loss of PGE, stimulation
of this fraction compared to other fractions. The bulk of the cyclase activity, how-
ever, did sediment with the heavy particulate fraction (Table 4).
The melanoma homogenates also exhibit phosphodiesterase and protein kinase
activities. Both of these cyclase-related enzymes appear primarily in the soluble
7-oxa,
13-Prostynoic Acid
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TABLE 4
SEDIMENTATION CHARACTERISTICS OF CYCLASE SYSTEM IN MELANOMA HOMOGENATESa
Time of
Tissue (g) centri-
sedimented fugation Basal activity MSH stimulated PGE, stimulatedl
1,000 k) hr 1.5 (33%) 3.1(46%) 6.5 (54%)
10,000 ,hr 0.9 (20%) 1.0 (15%) 2.3 (19%)
50,000 1 hr 0.7 (16%) 0.5 (7%) 1.4 (12%)
200,000 1 hr 0.5 (11%) 0.5 (7%) 0.7 (6%)
200,000
Supernatant 1 hr 0.9 (20%) 1.7 (25%) 1.1 (9%)
Homogenate 1.0 (100%) 1.2 (100%) 4.3 (100%)
a Specific activities are expressed as nmoles/10 min/mg of protein. Numbers in parentheses are the
percentages of total basal, and hormone- or PGEI-stimulated activity. Sedimented particulate frac-
tions were suspended in an equal volume of reaction buffer. [MSH] was 50 ,ug/ml and [PGE1] was
10 ,ug/ml.
fraction. The phosphodiesterase hydrolyzed 2.6 nmoles of cAMP/mg protein and
showed the usual sensitivity to methyl xanthines. The protein kinase incorporated
7.2 pmole of acid-precipitable PO4 into histone/min/mg protein in response to
10-6 M cAMP.
The melanoma cyclase was also evaluated as a slice preparation. Basal levels
of cyclic AMP (1.4 pmole/mg of tissue) were markedly increased by MSH (5.3
pmoles) and PGE1 (6.1 pmoles). Attempts were made to detect ectopic receptors
with parathormone, vasopressin, glucagon, TSH, and FSH. The melanoma slices
showed hormone sensitivity which was confined to PGE1, MSH, and related
(ACTH) peptides. Half-maximal activation of melanoma-homogenate cyclase is
seen at 5 X 10-7 M MSH. The slice preparation showed half-maximal activation
at 2 X 10-7 M MSH, a concentration somewhat higher than would be expected
to function in vivo.
In view of the effect of PGE1 on mammalian melanocytes, its efficacy in am-
phibian melanocytes was also examined. Preliminary experiments with pigmented
dorsal frog skin indicate that prostaglandin E1 at 10ttg/ml darkens the skin to nearly
the same final optical density as MSH and with a comparable rate of darkening.
Also, PGE1 raises levels of cyclic AMP in dorsal frog skin. In the absence of added
stimulators the cyclic AMP levels are 0.13 pmoles cAMP/mg of protein, with 50
ug/ml of MSH 0.67 pmoles cAMP/mg protein, and with 10 ,fg/ml of PGE1 0.43
pmoles cAMP/mg of protein.
DISCUSSION
Regulation of the adenyl cyclase system in the mouse Cloudman melanoma is
quite complex, and appears to involve prostaglandins and calcium as well as MSH.
The cyclase of the melanoma shows a marked and selective response to PGE1 even
in broken-cell preparations. Prostaglandin activation of broken-cell adenyl cyclase
of this magnitude has not been observed in other tissues. The stimulation of cyclase
by PGE1 is significantly greater than the stimulation produced by porcine MSH.
Since the amino acid sequence of mouse MSH is not known it is conceivable,
though unlikely, that this apparent greater efficacy of PGE1 rests in the preference
of the tissue for murine rather than porcine MSH. Such a preference for murine
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MSH could not be the result of greater binding affinity since both the prosta-
glandins and the peptides are being used at the saturating concentrations. Further,
there is no species variation for all of the c&MSH peptides (five species) which
have thus far been sequenced. It seems rather that the potential for activation
is greater for the prostaglandins than for the peptides, and that prostaglandins are
important regulators of the melanoma cyclase.
We emphasize that when melanocyte peptides are used in combination with the
prostaglandins they provide additional stimulation of cyclase. This additivity sug-
gests that hormones and prostaglandins activate cyclase through distinct pathways
although it might instead be due to contributions of other cell types such as capil-
laries (16). The additivity, coupled with the fact that MSH has no effect on prosta-
glandin synthetase, suggests that prostaglandins are not obligatory intermediates
in the cyclase-activation sequence. Further, while indomethacin, which is a known
inhibitor of prostaglandin synthetase (20), does, in fact, inhibit the activation of
melanoma cyclase by MSH, it does so at concentrations 100 times greater than
those required to inhibit prostaglandin synthetase. Hence, the inhibitor may act
at the hormone receptor or some other locus and have little if anything to do with
prostaglandin synthesis in the homogenate or washed-particle preparations in which
cyclase is being assayed. On the other hand, activation by MSH as well as PGE1
is antagonized in a seemingly competitive manner by 7-oxa-13-prostynoic acid.
Also, our data do not exclude the possibility that the hormone (MSH) promotes
release of sequestered endogenous prostaglandins.
The requirement for calcium in the activation of melanoma cyclase by MSH
is analogous to the calcium requirement for activation of adrenal cortical cyclase
by ACTH (21). The lack of a calcium requirement in the activation of melanoma
cyclase by prostaglandins suggests that MSH and prostaglandins insert into the
cyclase-activation sequence at different points. Certainly the profound structural
dissimilarities between the two classes of activators is compatible with the concept
that they possess independent binding sites for activation of cyclase.
The presence of a cyclic AMP-activated protein kinase in the melanoma is not
surprising, since such an enzyme has been demonstrated or implicated as a member
of the sequence by which cyclic AMP promotes the elaboration of hormone-
directed specialized cell function in many tissues. Melanoma protein kinase may
mediate the cyclic AMP-directed induction of tyrosinase, and thus participate in
the regulation of pigment synthesis. The fact that in at least some amelanotic
melanomas the cyclase system is intact up to and including the protein kinase,
suggests that the lesion in melanin synthesis in such tumors is probably distal to
the protein kinase.
Although the cyclase apparatus has been unequivocably implicated in the essen-
tial regulation of pigment metabolism, more data are needed in the definition of
the components actually involved in pigment synthesis and movement of pigment
granules; that is to say the targets of the cyclic AMP-activated protein kinase re-
main unknown. Recent observations with cytochalasin suggest the possibility that
microfilaments may participate in the cyclic AMP-directed darkening of melano-
cytes (22, 23).
SUMMARY
Adenyl cyclase has been examined in broken-cell and slice preparations in a
transplantable Cloudman melanoma. Activation by a or 8 MSH (melanocyte-stim-
590MELANOMA ADENYL CYCLASE 591
ulating hormone) of melanoma adenyl cyclase requires the presence of millimolar
calcium and is prevented by EGTA. (Activity increases from 3 to 10 nmoles of
cAMP/10 min/mg.) Prostaglandin E1 activates melanoma adenyl cyclase 1.5-2
times as much as MSH. Prostaglandin E, is half as effective as MSH and prosta-
glandins F1,, F2a, A, and B have very slight activity. Calcium is not required for
activation of melanoma cyclase by the prostaglandins. 7-oxa-13-prostynoic acid
and indomethacin interfere with activation by MSH. In the case of indometha-
cin the levels required for inhibition are two orders of magnitude higher than those
which inhibit prostaglandin synthetase. MSH does not stimulate prostaglandin syn-
thesis (accumulation of E2 or F2,a) in broken-cell preparations of the melanoma.
There is a partial additivity between prostaglandin E1 and MSH stimulationl of
melanoma cyclase. The data support the existence of two separate cyclase receptors
in the melanoma, one responsive to prostaglandin E1 and the second to MSH. MSH
does not appear to stimulate cyclase by stimulating prostaglandin synthetase. Re-
lease of stored prostaglandins, however, or stimulation of the synthesis of prosta-
glandin procursors by MSH cannot be excluded at present. Prostaglandin E1 has
also been found to mimic MSH in frog skin causing both increases in cyclic-AMP
levels and darkening.
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